Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare Inc. (PBH) Stock Competitors & Peer Comparison
See (PBH) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PBH | $56.27 | -3.48% | 2.8B | 15.18 | $3.87 | N/A |
| MCK | $829.51 | +0.14% | 102.2B | 24.11 | $34.61 | +0.38% |
| COR | $311.54 | +0.44% | 60.7B | 37.52 | $8.32 | +0.73% |
| CAH | $203.50 | +0.57% | 48.4B | 29.59 | $6.95 | +0.99% |
| ABC | $179.98 | -0.23% | 36.1B | 21.92 | $8.21 | N/A |
| HSIC | $74.32 | -3.73% | 8.7B | 23.28 | $3.27 | N/A |
| PDCO | $31.33 | +0.00% | 2.8B | 20.48 | $1.53 | +1.66% |
| GRDN | $37.80 | -0.34% | 2.4B | 48.19 | $0.78 | N/A |
| ACH | $3.71 | +8.48% | 292.8M | -2.86 | -$1.34 | N/A |
| OMI | $2.68 | +8.94% | 207.1M | -0.47 | -$5.69 | N/A |
Stock Comparison
PBH vs MCK Comparison April 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.8B. In comparison, MCK has a market cap of 102.2B. Regarding current trading prices, PBH is priced at $56.27, while MCK trades at $829.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 15.18, whereas MCK's P/E ratio is 24.11. In terms of profitability, PBH's ROE is +0.10%, compared to MCK's ROE of -2.45%. Regarding short-term risk, PBH is more volatile compared to MCK. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check MCK's competition here
PBH vs COR Comparison April 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.8B. In comparison, COR has a market cap of 60.7B. Regarding current trading prices, PBH is priced at $56.27, while COR trades at $311.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 15.18, whereas COR's P/E ratio is 37.52. In terms of profitability, PBH's ROE is +0.10%, compared to COR's ROE of +1.01%. Regarding short-term risk, PBH is more volatile compared to COR. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check COR's competition here
PBH vs CAH Comparison April 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.8B. In comparison, CAH has a market cap of 48.4B. Regarding current trading prices, PBH is priced at $56.27, while CAH trades at $203.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 15.18, whereas CAH's P/E ratio is 29.59. In terms of profitability, PBH's ROE is +0.10%, compared to CAH's ROE of -0.59%. Regarding short-term risk, PBH is more volatile compared to CAH. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check CAH's competition here
PBH vs ABC Comparison April 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.8B. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, PBH is priced at $56.27, while ABC trades at $179.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 15.18, whereas ABC's P/E ratio is 21.92. In terms of profitability, PBH's ROE is +0.10%, compared to ABC's ROE of +1.01%. Regarding short-term risk, PBH is more volatile compared to ABC. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check ABC's competition here
PBH vs HSIC Comparison April 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.8B. In comparison, HSIC has a market cap of 8.7B. Regarding current trading prices, PBH is priced at $56.27, while HSIC trades at $74.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 15.18, whereas HSIC's P/E ratio is 23.28. In terms of profitability, PBH's ROE is +0.10%, compared to HSIC's ROE of +0.12%. Regarding short-term risk, PBH is more volatile compared to HSIC. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check HSIC's competition here
PBH vs PDCO Comparison April 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.8B. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, PBH is priced at $56.27, while PDCO trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 15.18, whereas PDCO's P/E ratio is 20.48. In terms of profitability, PBH's ROE is +0.10%, compared to PDCO's ROE of +0.06%. Regarding short-term risk, PBH is more volatile compared to PDCO. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check PDCO's competition here
PBH vs GRDN Comparison April 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.8B. In comparison, GRDN has a market cap of 2.4B. Regarding current trading prices, PBH is priced at $56.27, while GRDN trades at $37.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 15.18, whereas GRDN's P/E ratio is 48.19. In terms of profitability, PBH's ROE is +0.10%, compared to GRDN's ROE of +0.28%. Regarding short-term risk, PBH is more volatile compared to GRDN. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check GRDN's competition here
PBH vs ACH Comparison April 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.8B. In comparison, ACH has a market cap of 292.8M. Regarding current trading prices, PBH is priced at $56.27, while ACH trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 15.18, whereas ACH's P/E ratio is -2.86. In terms of profitability, PBH's ROE is +0.10%, compared to ACH's ROE of +7.33%. Regarding short-term risk, PBH is less volatile compared to ACH. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check ACH's competition here
PBH vs OMI Comparison April 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.8B. In comparison, OMI has a market cap of 207.1M. Regarding current trading prices, PBH is priced at $56.27, while OMI trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 15.18, whereas OMI's P/E ratio is -0.47. In terms of profitability, PBH's ROE is +0.10%, compared to OMI's ROE of +7.33%. Regarding short-term risk, PBH is less volatile compared to OMI. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check OMI's competition here
PBH vs GEG Comparison April 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.8B. In comparison, GEG has a market cap of 56.9M. Regarding current trading prices, PBH is priced at $56.27, while GEG trades at $2.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 15.18, whereas GEG's P/E ratio is -4.20. In terms of profitability, PBH's ROE is +0.10%, compared to GEG's ROE of -0.21%. Regarding short-term risk, PBH is more volatile compared to GEG. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check GEG's competition here
PBH vs HX Comparison April 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.8B. In comparison, HX has a market cap of 53.4M. Regarding current trading prices, PBH is priced at $56.27, while HX trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 15.18, whereas HX's P/E ratio is -1.84. In terms of profitability, PBH's ROE is +0.10%, compared to HX's ROE of -1.07%. Regarding short-term risk, PBH is less volatile compared to HX. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check HX's competition here
PBH vs WGRX Comparison April 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.8B. In comparison, WGRX has a market cap of 8.2M. Regarding current trading prices, PBH is priced at $56.27, while WGRX trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 15.18, whereas WGRX's P/E ratio is -0.08. In terms of profitability, PBH's ROE is +0.10%, compared to WGRX's ROE of +1417.60%. Regarding short-term risk, PBH is less volatile compared to WGRX. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check WGRX's competition here
PBH vs ZYXI Comparison April 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.8B. In comparison, ZYXI has a market cap of 3.8M. Regarding current trading prices, PBH is priced at $56.27, while ZYXI trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 15.18, whereas ZYXI's P/E ratio is -0.05. In terms of profitability, PBH's ROE is +0.10%, compared to ZYXI's ROE of -18.07%. Regarding short-term risk, PBH is more volatile compared to ZYXI. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check ZYXI's competition here
PBH vs SNYR Comparison April 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.8B. In comparison, SNYR has a market cap of 3.7M. Regarding current trading prices, PBH is priced at $56.27, while SNYR trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 15.18, whereas SNYR's P/E ratio is -0.30. In terms of profitability, PBH's ROE is +0.10%, compared to SNYR's ROE of +0.83%. Regarding short-term risk, PBH is less volatile compared to SNYR. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check SNYR's competition here
PBH vs MEHA Comparison April 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.8B. In comparison, MEHA has a market cap of 695.5K. Regarding current trading prices, PBH is priced at $56.27, while MEHA trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 15.18, whereas MEHA's P/E ratio is 10.10. In terms of profitability, PBH's ROE is +0.10%, compared to MEHA's ROE of +1.19%. Regarding short-term risk, PBH is less volatile compared to MEHA. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check MEHA's competition here
PBH vs RDGT Comparison April 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.8B. In comparison, RDGT has a market cap of 426. Regarding current trading prices, PBH is priced at $56.27, while RDGT trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 15.18, whereas RDGT's P/E ratio is -0.03. In terms of profitability, PBH's ROE is +0.10%, compared to RDGT's ROE of +0.42%. Regarding short-term risk, PBH is less volatile compared to RDGT. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check RDGT's competition here
PBH vs CVET Comparison April 2026
PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBH stands at 2.8B. In comparison, CVET has a market cap of 0. Regarding current trading prices, PBH is priced at $56.27, while CVET trades at $20.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBH currently has a P/E ratio of 15.18, whereas CVET's P/E ratio is -69.97. In terms of profitability, PBH's ROE is +0.10%, compared to CVET's ROE of -0.06%. Regarding short-term risk, PBH is more volatile compared to CVET. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check CVET's competition here